Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Published:2007-06-01 Issue:6 Volume:30 Page:1608-1610
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Vilsbøll Tina¹,Zdravkovic Milan²,Le-Thi Tu²,Krarup Thure¹,Schmitz Ole³,Courrèges Jean-Pierre⁴,Verhoeven Robert⁵,Bugánová Ingrid⁶,Madsbad Sten⁷

Affiliation:

1. Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark

2. Novo Nordisk, Bagsværd, Denmark

3. Århus Hospital, Århus, Denmark

4. Centre Hospitalier de Narbonne, Narbonne, France

5. Gelre Ziekenhuis, Apeldoorn, the Netherlands

6. Dibetologická Ambulancia, Zilina, Slovakia

7. Hvidovre Hospital, Copenhagen, Denmark

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/30/6/1608/598008/zdc00607001608.pdf

Reference11 articles.

1. Agerso H, Vicini P: Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharmacol Sci 19:141–150, 2003

2. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187–1194, 2004

3. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43:1664–1669, 2000

4. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:1335–1342, 2004

5. World Medical Association: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926, 1997

Cited by 389 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a high-yield recombinant clone for the enhanced production of a long-acting Glucagon like peptide-1 analogue with improved biological efficacy;Process Biochemistry;2024-12

2. Dumping Syndrome after Bariatric Surgery;Annali Italiani di Chirurgia;2024-08-20

3. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

4. Hepatic function of glucagon-like peptide-1 and its based diabetes drugs;Medical Review;2024-06-04

5. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity;Frontiers in Nutrition;2024-04-29